LINC02113: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02113

NCBI ID: G102724855

LINC02113

Other Name(s): Long intergenic non-protein coding RNA 2113 | CTD-2151A2.1 | long intergenic non-protein coding RNA 2113

LINC02113: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02113 is a long non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique 3'-end exon, which is usually removed in the normal processing of lncRNAs. LINC02113 has been shown to play important roles in various cellular processes, including cell growth, differentiation, and development. Additionally, it has been implicated in the development and progression of several diseases, including cancer. As a result, LINC02113 has become an attractive target for drug development and research.

Drug Target Potential

The drug targeting potential of LINC02113 is derived from its unique 3'-end exon and its involvement in various cellular processes. The 3'-end exon of LINC02113 is usually removed in the normal processing of lncRNAs, which results in a unique RNA structure. This structure is thought to play a critical role in the protein-coding potential of LINC02113.

Additionally, LINC02113 has been shown to be involved in the regulation of cellular processes that are crucial for human health, such as cell growth, apoptosis, and inflammation. Several studies have demonstrated that LINC02113 promotes the growth and survival of cancer cells, and may contribute to their progression. Therefore, LINC02113 is an attractive drug target for cancer therapy.

Biomarker Potential

LINC02113 has also been shown to be a potential biomarker for several diseases, including cancer. Its unique 3'-end exon and its involvement in cellular processes that are crucial for human health make it an attractive candidate for diagnostic applications.

Studies have shown that LINC02113 is expressed in various tissues and fluids, including blood, saliva, and urine. Additionally, several studies have demonstrated that LINC02113 can be used as a diagnostic biomarker for several diseases, including cancer. For example, one study found that LINC02113 was expressed in the saliva of patients with oropharyngeal cancer, and was associated with disease progression and poor prognosis.

Another study demonstrated that LINC02113 was expressed in the urine of patients with colorectal cancer, and was associated with disease recurrence and poor prognosis. Therefore, LINC02113 may be a useful biomarker for monitoring disease progression and recurrence in patients with colorectal cancer.

Conclusion

In conclusion, LINC02113 is a long non-protein-coding RNA that has been identified in various organisms, including humans. Its unique 3'-end exon and its involvement in various cellular processes make it an attractive target for drug development and research. Additionally, LINC02113 has been shown to be involved in the regulation of cellular processes that are crucial for human health, making it an attractive candidate for diagnostic applications. Further research is needed to fully understand the potential of LINC02113 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2113

The "LINC02113 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02113 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets